Posted on March 29, 2023 by: eqs Kintor Pharma Announces Completion of Subject Enrollment in Phase III Clinical Trial of KX-826 for Treatment of Male Androgenetic Alopecia in China
Posted on March 29, 2023 by: eqs Kintor Pharma Announces Completion of Subject Enrollment in Phase III Clinical Trial of KX-826 for Treatment of Male Androgenetic Alopecia in China
![](eager" fetchpriority="high" src="https://storage.googleapis.com/bucket_philpr/2023/03/0e4339df-ap22300708548233.jpg" srcset="/wp-content/uploads/2023/03/AP22300708548233.jpg?resize=120%2C80&quality=80 120w, /wp-content/uploads/2023/03/AP22300708548233.jpg?resize=270%2C180&quality=80 270w, /wp-content/uploads/2023/03/AP22300708548233.jpg?resize=375%2C250&quality=80 375w, /wp-content/uploads/2023/03/AP22300708548233.jpg?resize=570%2C380&quality=80 570w, https://philpr.com/wp-content/uploads/2023/03/0e4339df-ap22300708548233.jpg 770w" sizes="(max-width: 120px) 120px, (max-width: 270px) 270px, (max-width: 375px) 375px, (max-width: 570px) 570px, (max-width: 770px) 770px, 770px" alt="Trump)